Pages Menu
TwitterRssFacebookWhatsapplinkedin
ISSN (Online): 0975-8232,
ISSN (Print): 2320-5148

International Journal Of
Pharmaceutical Sciences And Research

IJPSR is indexed with Embase

An International Journal published monthly
An Official Publication of Society of Pharmaceutical Sciences and Research

Categories Menu

Posted by on Feb 1, 2014 in | 0 comments

GREEN PHARMACY: AN ALTERNATIVE AND COMPLEMENTARY MEDICINE

The people in India have an outstanding knowledge of medicinal plants acquired over centuries.A passion for studying medicinal plants is evident both in folk and scholarly traditions. The indigenous mode of understanding and using plants is different from the modern scientific way. It includes botanical, medical and astrological elements. This is the basis of green pharmacy. Indians obviously care for medicinal plants because they know so many of them, so much about them and have worked extensively on their application. It is a remarkable fact that the use of medicinal plants is still a living tradition in the form of a million village-based folk carriers. These traditional birth attendants, bonesetters, herbal healers and wandering monks are invisible to policy makers and therefore not taken into account as a public health resource. Apart from these specialised folk healers there are also millions of women and elders with traditional knowledge of food and nutrition and herbal home-remedies. However, the revitalisation of this vast and diverse folk tradition does not appear on...

Read More

Posted by on Feb 1, 2014 in | 0 comments

REVIEW ON NON-VIRAL DELIVERY SYSTEMS FOR siRNA

The emergence of RNAi, has found new horizons in siRNA as drug molecule. This technology offers a great promise in the achieving efficient treatment.  There is a demand for designing efficient siRNA delivery systems/ vehicles that can achieve targeted delivery and replicate the invitro success. The siRNA delivery system selection is based on target cell type. The siRNA delivery systems are categorized as viral and non-viral delivery systems. Non-viral delivery system includes liposomes; polymers; peptides etc. are the widely studied delivery systems for siRNA. Non-viral delivery systems have advantages of control over functionality and industrial scalability. Liposomes were one of the first studied siRNA non-viral delivery systems which with time have evolved on account of modifications on certain attributes like surface charge, surface tagging, composition etc. Peptides and Polymers are the recent addition to the non-viral siRNA delivery vehicles on account of biocompatibility factor. This review clubs the non-viral siRNA delivery systems which have attracted research and have shown efficiency in the clinical...

Read More

Posted by on Feb 1, 2014 in | 0 comments

APPROACHES AND SIGNIFICANCE OF TRANSDERMAL DRUG DELIVERY SYSTEMS: A REVIEW

Transdermal Drug Delivery System (TDDS) is the most innovative and Novel drug delivery systems by penetrating through the skin by increasing the scope of molecules that can be delivered.  TDDS that traditionally uses a patch containing loaded drug substances pressed on to the skin is convenient, painless and non-invasive, to avoid gastro intestinal (GI) tract toxicity (peptic ulcer disease). Transdermal delivery not only provides controlled, constant administration of the drug, but also allows continuous input of drugs with short biological half-lives and eliminates pulsed entry into systemic circulation which often causes undesirable side effect. The number of medications and the ways in which they can be administered have expanded dramatically over the years. One such advancement is the development of transdermal patch delivery systems. Transdermal drug technology specialists are continuing to search for new methods that can effectively and painlessly deliver larger molecules in therapeutic quantities to overcome the difficulties associated with the oral route. Various products of TDDS are in use by applying approaches like micro needles, abrasion,...

Read More

Posted by on Feb 1, 2014 in | 0 comments

AN UPDATE ON AYURVEDIC HERB HENNA (LAWSONIA INERMIS L.): A REVIEW

Lawsonia inermis L. is a much branched glabrous shrub or small tree, cultured for its leaves although stem bark, roots, flowers and seeds have also been used in traditional medicine. It has been traditionally reported in use of headache, hemicranias, lumbago, bronchitis, boils, ophthalmia, syphilitis, sores, amenorrhea, scabies, diseases of the spleen, dysuria, bleeding disorder, skin diseases, diuretic, antibacterial, antifungal, anti-amoebiasis, astringent, anti-hemorrhagic, hypotensive and sedative effect. The plant is reported to contain Lawsone, Esculetin, Fraxetin, Isoplumbagin, Scopoletin, Betulin, Betulinic acid, Hennadiol, Lupeol, Lacoumarin, Laxanthone, Flavone glycosides, two pentacytic triterpenes. The plant is reported to contain carbohydrates, proteins, flavonoids, tannins and phenolic compounds, alkaloids, terpenoids, quinones, coumarins, xanthones and fatty acids. The plant has been reported to have analgesic, hypoglycemic, hepatoprotective, immunostimulant, anti-inflammatory, antibacterial, antimicrobial, antifungal, antiviral, antiparasitic, antitrypanosomal, antidermatophytic, antioxidant, antifertility, tuberculostatic and anticancer properties. It is now measured as a valuable source of exclusive natural products for growth of medicines against various diseases and also for the development of industrial products. This review gives a bird’s eye...

Read More

Posted by on Feb 1, 2014 in | 0 comments

PROTEASOME INHIBITORS FOR USE IN MULTIPLE MYELOMA

The approval of first-in-class proteasome inhibitor bortezomib in 2003, made possible the therapeutic validation of proteasome as a target for use in discovery and development of new treatment options in cancer, particularly haematological conditions like Multiple Myeloma. However, this breakthrough drug discovery suffered from a few limitations. As a result, the discovery of bortezomib not only introduced to the pharmaceutical research community a new area but alsoprovided the impetus to work for a better future. The result was the recent approval of carfilzomib for use in relapsed and refractory multiple myeloma which revived the lagging area again and brought an upsurge in the area of research and development for second generation proteasome inhibitors directed towards this therapy. Here, we present a review on these second generation proteasome inhibitors currently in clinical or preclinical phase and try to assess the future for multiple myeloma...

Read More